AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18190710
Drug: Probiotic containing
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic containing 4 strains of live bacteria taken daily for 3 months
Trial: 18190710
Drug: Identical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Identical placebo taken daily for 3 months
Trial: 12711121
Drug: Gemcitabine (GEM)
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine (GEM) 1000 mg/m(2), days 1, 8 and 15, every 4 weeks
Trial: 12711121
Drug: Cisplatin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (100 mg/m(2), day 1) plus Vindesine (3 mg/m(2), days 1 and 15) (PV)
Trial: 10921160
Drug: Zhu Yu
RxNorm normalized name: Cang zhu
DrugBank: Atractylodes lancea root (DB14693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zhu Yu Hua Tan Tang plus general treatment
Trial: 1570392
Drug: pindolol (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pindolol (80 mg over 3 days)
Trial: 1570392
Drug: buspirone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: buspirone (30 mg orally)
Trial: 30044439
Drug: Anthocyanines (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthocyanines (60 mg/day)
Trial: 30044439
Drug: Xanthophylls (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xanthophylls (6 mg L + 2 mg Z/day)
Trial: 30044439
Drug: Anthocyanines (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthocyanines (60 mg/day) + Xanthophylls (6 mg L + 2 mg Z/day)
Trial: 27454919
Drug: Corticosteroid-free regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid-free regimen with Tac and MMF starting at 3 g/d, dose adjusted from day 5
Trial: 27454919
Drug: Corticosteroid regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid regimen with Tac and fixed-dose MMF (2 g/d)
Trial: 9246136
Drug: Prednisolone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (1 mg/kg/day orally for seven days)
Trial: 8502357
Drug: Sygen‐‐monosialoganglioside 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sygen‐‐monosialoganglioside 40 mg daily
Trial: 2692819
Drug: Diflunisal (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal (500 mg orally, twice daily)
Trial: 3329968
Drug: Piroxicam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam (20 mg orally, once daily)
Trial: 31278194
Drug: Ferric citrate
RxNorm normalized name: Ferric Citrate
DrugBank: Ferric sodium citrate (DB13771)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric citrate coordination complex (two tablets per meal, 210 mg ferric iron per tablet)
Trial: 24978872
Drug: Spironolactone 25
RxNorm normalized name: spironolactone 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 25 mg/day (up to 100 mg/day)
Trial: 17515857
Drug: Antithrombin III
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombin III (AT) agent at 1,500 U/24 h (combined group) for 3 days
Trial: 17515857
Drug: Antithrombin III
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombin III (AT) agent at 500 U/8 h (divided group) for 3 days
Trial: 16264051
Drug: Aspergillus fumigatus
RxNorm normalized name: Aspergillus Fumigatus
DrugBank: Aspergillus fumigatus (DB10425)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspergillus fumigatus inhalation
Trial: 11850098
Drug: Acarbose, 100
RxNorm normalized name: Acarbose, 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose, 100 mg thrice daily
Trial: 11850098
Drug: Glibenclamide, 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide, 1 mg thrice daily
Trial: 109592
Drug: 10 or
RxNorm normalized name: K-10 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 or 50 microgram doses of meningococcal group A polysaccharide vaccine
Trial: 109592
Drug: 50 microgram
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microgram dose of meningococcal group A polysaccharide vaccine
Trial: 109592
Drug: 10 microgram
RxNorm normalized name: Estradiol 10 microgram vaginal tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 microgram dose of meningococcal group A polysaccharide vaccine
Trial: 23897241
Drug: Endotracheal tube
RxNorm normalized name: Sus scrofa fallopian tube preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endotracheal tube cleaning twice daily (group B)
Trial: 21827704
Drug: Latex sublingual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latex sublingual immunotherapy
Trial: 9582586
Drug: Ciprofloxacin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (100 mg)
Trial: 30626285
Drug: Transdermal glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal glyceryl trinitrate (GTN) for 7 days
Trial: 25906949
Drug: Boron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boron supplementation (10 mg/day)
Trial: 20335550
Drug: 1 capsule/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule/day of omega-3 PUFA supplement providing 0.84 g DHA + EPA
Trial: 20335550
Drug: 3 capsules/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 capsules/day of omega-3 PUFA supplement providing 2.52 g DHA + EPA
Trial: 20335550
Drug: 6 capsules/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 capsules/day of omega-3 PUFA supplement providing 5.04 g DHA + EPA
Trial: 20335550
Drug: 9 capsules/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 capsules/day of omega-3 PUFA supplement providing 7.56 g DHA + EPA
Trial: 16131771
Drug: Intravenous diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diazepam (without prior i.v. access)
Trial: 16131771
Drug: Intravenous diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diazepam (with prior i.v. access)
Trial: 10503678
Drug: Iron treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron treatment for pupils with s-ferritin <15 microg/l, duration of 3 months
Trial: 8607723
Drug: Active drug
RxNorm normalized name: Capillary active drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug treatment (chlorthalidone 15 mg/d, acebutolol hydrochloride 400 mg/d, doxazosin mesylate 2 mg/d, amlodipine besylate 5 mg/d, enalapril maleate 5 mg/d)
Trial: 8607723
Drug: Active drug
RxNorm normalized name: Capillary active drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug treatment (all active drugs combined)
Trial: 1953524
Drug: Interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alpha 2b (3 million units subcutaneously thrice weekly for 24 weeks)
Trial: 1953524
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (observed without treatment for 12 months)
Trial: 25163906
Drug: Cilengitide 2000
RxNorm normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilengitide 2000 mg intravenously twice weekly combined with temozolomide chemoradiotherapy
Trial: 19648823
Drug: Raltegravir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir (400 mg twice a day after 48 weeks)
Trial: 19648823
Drug: Efavirenz (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz (600 mg every day)
Trial: 8800392
Drug: Naltrexone (NTX),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (NTX), 50 mg/day, po
Trial: 1731285
Drug: Transdermal E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal E2 0.1 mg for 24.5 days of each 28‐day cycle for 96 weeks
Trial: 1731285
Drug: Transdermal E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal E2 0.1 mg plus 10 mg of medroxyprogesterone acetate from days 13‐25 of each cycle
Trial: 31003690
Drug: Topical sesame
RxNorm normalized name: Sesame Oil
DrugBank: Sesame oil (DB11172)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical sesame oil with massage (10 drops, twice a day for 7 days)
Trial: 24988438
Drug: RAL 800
RxNorm normalized name: ABSTRAL 800mcg Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAL 800 mg by chewing
Trial: 24988438
Drug: RAL 400
RxNorm normalized name: Sectral 400mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAL 400 mg by swallowing
Trial: 19865065
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 terclatrate (QTer) 200 mg orally once daily for 7 days before noise exposure
Trial: 9158165
Drug: Clonidine (transdermal,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (transdermal, given for 5 days)
Trial: 25906565
Drug: Triple-strong stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-strong stimulation therapy group
Trial: 25906565
Drug: Acupoint plaster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint plaster therapy group
Trial: 19784467
Drug: InGaAlP laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: InGaAlP laser (660 nm) and GaAlAs laser (780 nm), 25 mW potency, 6.3J/cm(2) dose, 10‐s irradiation time, followed by conventional treatment (Mucositis Formula)
Trial: 19784467
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (Mucositis Formula) only
Trial: 15116086
Drug: Both dietary
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both dietary treatments
Trial: 14649615
Drug: 4-minute, 1.23%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-minute, 1.23% APF gel treatment
Trial: 14649615
Drug: AL irradiation
RxNorm normalized name: AL-034
DrugBank: AL-034 (DB17471)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AL irradiation followed by APF gel treatment
Trial: 6700643
Drug: Dexamethasone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (4 mg every 6 hours for 48 hours)
Trial: 30327362
Drug: Insulin Pump
RxNorm normalized name: insulin pump syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin Pump
Trial: 2336873
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with a vaccine consisting of autoclaved Mycobacterium w
Trial: 2336873
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and placebo injections
Trial: 377219
Drug: Weekly immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly immunotherapy combining BCG and irradiated leukaemic cells
Trial: 377219
Drug: Monthly reinduction
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly reinduction chemotherapy
Trial: 25744500
Drug: Accelerated high-frequency
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Accelerated high-frequency (HF) rTMS treatment
Trial: 19447570
Drug: Sustained-release (SR)
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release (SR) bupropion plus transdermal nicotine patch
Trial: 9270638
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy (cisplatin and 5-fluorouracil)
Trial: 9270638
Drug: Surgical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical therapy alone
Trial: 27852098
Drug: Water plus
RxNorm normalized name: Premium Gripe Water Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water plus 100 mg simethicone (group B)
Trial: 27852098
Drug: Water plus
RxNorm normalized name: Premium Gripe Water Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water plus 100 mg simethicone plus 600 mg N-acetylcysteine (group C)
Trial: 24018711
Drug: Tamsulosin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.4 mg o.d.) and ketoconazole (200 mg t.d.s.)
Trial: 24018711
Drug: Tamsulosin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.4 mg o.d.) and placebo
Trial: 21233029
Drug: Budesonide 64
RxNorm normalized name: budesonide 64 MCG/ACTUAT Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 64 μg/dose nasal spray
Trial: 21233029
Drug: Budecort Aqua®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budecort Aqua® 64 μg/dose nasal spray
Trial: 18653484
Drug: Licofelone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licofelone (200 mg twice a day)
Trial: 14700144
Drug: 10 per
RxNorm normalized name: 10 Person ANSI KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 per cent sulfur ointment
Trial: 14700144
Drug: 0.3 per
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 per cent gamma benzene hexachloride gel
Trial: 25359382
Drug: COBRA Classic
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: COBRA Classic (methotrexate (MTX)+ sulfasalazine+60 mg prednisone tapered to 7.5 mg daily from W7)
Trial: 25359382
Drug: COBRA Slim
RxNorm normalized name: benzalkonium chloride Topical Foam [DigiClean Slim-Line]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COBRA Slim (MTX+30 mg prednisone tapered to 5 mg from W6)
Trial: 25359382
Drug: COBRA Avant-Garde
RxNorm normalized name: Eco-Gard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COBRA Avant-Garde (MTX+leflunomide+30 mg prednisone tapered to 5 mg from W6)
Trial: 8104978
Drug: Twice-daily skin
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily skin preparation with 10% aqueous povidone-iodine for 48 h preoperatively (Group A, N = 34)
Trial: 8104978
Drug: No skin
RxNorm normalized name: Aveeno Skin Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No skin preparation (Group B, N = 30)
Trial: 3516177
Drug: Ampicillin sodium/amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin sodium/amoxicillin trihydrate therapy
Trial: 31054010
Drug: Probiotic (Symprove™,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic (Symprove™, 1 ml/kg/day for 4 weeks)
Trial: 18207598
Drug: Low-dose daily
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose daily cisplatin
Trial: 18207598
Drug: Hyperfractionated radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyperfractionated radiotherapy (77Gy in 70 fractions in 35 treatment days)
Trial: 9171065
Drug: Methylprednisolone (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (80 mg in 8 ml of isotonic saline)
Trial: 9171065
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline (1 ml)
Trial: 31959707
Drug: Direct Oral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct Oral Anticoagulants (DOA)
Trial: 23774797
Drug: LDA 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDA 100 mg (regimen A)
Trial: 23774797
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg (regimen C)
Trial: 23774797
Drug: LDA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDA with rabeprazole 10 mg (regimen AC)
Trial: 16571279
Drug: Taizhi'an capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taizhi'an capsule (TZA) 0.9 g 3 times a day + Simvastatin (Sim) 10 mg at bedtime
Trial: 16571279
Drug: Simvastatin (Sim)
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin (Sim) 20 mg at bedtime
Trial: 7750187
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated oestrogens (OCE, 0.625 mg) + Medroxyprogesterone acetate (MPA, 5 mg)
Trial: 7750187
Drug: Transdermal oestradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal oestradiol (TE, 50 micrograms) + Medroxyprogesterone acetate (MPA, 5 mg)
Trial: 2212918
Drug: Metronidazole 1
RxNorm normalized name: metronidazole 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 1 g daily for 7 days
Trial: 7067925
Drug: Tinidazole 2
RxNorm normalized name: tinidazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole 2 g single dose
Trial: 31769240
Drug: Insulin Degludec/Insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin Degludec/Insulin Aspart (IDegAsp)
Trial: 27756182
Drug: Theaflavin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theaflavin (50 or 100 mg/day)
Trial: 27756182
Drug: Catechin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Catechin (400 mg/ml)
Trial: 16638862
Drug: Concurrent high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent high-dose IL-2
Trial: 16638862
Drug: Recombinant vaccinia
RxNorm normalized name: Dna (recombinant vaccinia virus strain livp clone gl-onc1)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant vaccinia and fowlpox vaccines
Trial: 16638862
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment with IL-2
Trial: 8508692
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg oral ciprofloxacin administered 1, 2 or 3 hours before anesthesia
Trial: 8508692
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg gentamicin plus 500 mg metronidazole administered intravenously
Trial: 22285278
Drug: SQ-standardized grass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ-standardized grass allergy immunotherapy tablet (Grazax)
Trial: 18712620
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release (SR) tablets of dextromethorphan hydrobromide
Trial: 18712620
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release tablets of dextromethorphan hydrobromide
Trial: 15968890
Drug: CO2 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CO2 treatment for 18 days
Trial: 1351600
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese herbal therapy (TCHT)
Trial: 3880780
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of terodiline and meladrazine
Trial: 30634203
Drug: Shenkang Injection
RxNorm normalized name: CAMPHOR (SYNTHETIC) 4.28 mg in 100 mg / MENTHOL 2.84 mg in 100 mg / METHYL SALICYLATE 1.4 mg in 100 mg TRANSDERMAL PLASTER [Shennong Analgesic Plaster]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenkang Injection (SI)
Trial: 30634203
Drug: Rehydration therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehydration therapy (normal saline)
Trial: 30634203
Drug: 5% glucose
RxNorm normalized name: Dextrose/Water 5% Oral Solution [ENFAMIL 5% GLUCOSE IN WATER]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% glucose injection (control)
Trial: 20158295
Drug: Negative affect
RxNorm normalized name: GLYCERIN NEGATIVE CONTROL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative affect cue (speech preparation task)
Trial: 12182909
Drug: front-loaded rt-PA
RxNorm normalized name: rt-PA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: front-loaded rt-PA (up to 100 mg)
Trial: 12182909
Drug: TNK-tPA (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNK-tPA (single bolus up to 50 mg)
Trial: 10469772
Drug: Dexamethasone (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.25 mg/kg on days 1-7, 0.12 mg/kg on days 8-14, 0.05 mg/kg on days 15-21, 0.02 mg/kg on days 21-28)
Trial: 1725549
Drug: Calcium blockers
RxNorm normalized name: CALCIUM CHANNEL BLOCKERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium blockers (diltiazem)
Trial: 1725549
Drug: Calcium antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium antagonists (dihydropiridines)
Trial: 1725549
Drug: Calcium blockers
RxNorm normalized name: CALCIUM CHANNEL BLOCKERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium blockers and ACE inhibitors
Trial: 366143
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg levamisole once weekly
Trial: 6218948
Drug: 350 mg
RxNorm normalized name: hemin 350 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 350 mg daily doses of levamisole for 3 consecutive days weekly
Trial: 17906163
Drug: Tadalafil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (5 mg/d) with doxazosin (1, 2, and 4 mg/d)
Trial: 17906163
Drug: Tadalafil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil (5 mg/d) with tamsulosin (0.4 mg/d)